Table of Contents

A Letter from Pfizer's Chairman & Chief Executive Officer			i
A Message from Pfizer's Lead Independent Director			iv
Notice of 2025 Annual Meeting and Proxy Statement			vi
Our Business and Strategy			1
Item 1 — Election of Directors			6
Criteria for Board Membership	6	Our 2025 Director Nominees	8
Selection of Candidates	6	Director Nominees	11
Director Independence	7		
Governance			18
Overview	18	Governance Committee Report	24
Governance Materials Available on Our Website	18	Regulatory and Compliance Committee Report	25
The Board's Leadership Structure	18	Investor Outreach	26
The Board's Role in Risk Oversight	19	Public Policy Engagement and Political Participation	29
The Board's Role in Succession Planning	20	Pfizer Policies on Business Conduct	31
Evaluation of Board Effectiveness	21	Other Governance Practices and Policies	32
Board and Committee Information	21		
Non-Employee Director Compensation			33
2024 Director Compensation Table	34		
Securities Ownership			35
Beneficial Owners	36	Delinquent Section 16(a) Reports	36
Item 2 — Ratification of Selection of Independent Registered P	ublic A	ccounting Firm	37
Audit and Non-Audit Fees	38	•	
Audit Committee Report			39
Item 3 — 2025 Advisory Approval of Executive Compensation			40
2024 Advisory Vote on Executive Compensation	40	2025 Advisory Vote on Executive Compensation	41
2024 Pay-for-Performance	40		
Compensation Committee Report			42
Executive Compensation			43
Compensation Discussion and Analysis	43	Compensation Tables	70
Executive Summary	44	Financial Measures	92
Shareholder Proposals			93
Item 4 — Shareholder Vote Regarding Golden Parachutes	93	Item 5 — Issue a Report Evaluating the Risks Related to Religious Discrimination Against Employees	96
Annual Meeting Information			98
Annual Meeting	98	Other Business	103
Voting	99	Submitting Proxy Proposals and Director Nominations for	104
Proxy Materials	102	the 2026 Annual Meeting	
Other Questions	103		